Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Compromise Medicare Rx Benefit Will Be Next Step For Senate, Daschle Says

Executive Summary

Compromise Medicare drug benefit language will be negotiated once the Senate rejects the current Rx proposals, Senate Majority Leader Tom Daschle (D-S.D.) predicted

You may also be interested in...



Medicare Rx Moves To Campaign Trail; AARP Endorses Stripped Down Bill

The Medicare prescription drug benefit debate is moving from Capitol Hill to the campaign trail after the Senate failed to reach agreement on a bill before the August recess

Medicare Rx Moves To Campaign Trail; AARP Endorses Stripped Down Bill

The Medicare prescription drug benefit debate is moving from Capitol Hill to the campaign trail after the Senate failed to reach agreement on a bill before the August recess

Medicare Rx Discussions In Senate Focus On Low-Income/Catastrophic Bill

A potential compromise Medicare drug benefit plan would address pharmacy concerns about a Medicare-endorsed Rx discount card, HHS Secretary Thompson told the National Association of Sate Legislatures in Denver July 26

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel